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To summarize current and emerging imaging techniques that can be used to assess neuro-
protection and repair in multiple sclerosis (MS), and to provide a consensus opinion on the
potential utility of each technique in clinical trial settings.
Methods
Clinicians and scientists with expertise in the use of MRI in MS convened in Toronto, Canada, in
November 2016 at a North American Imaging in Multiple Sclerosis (NAIMS) Cooperative
workshop meeting. The discussion was compiled into a manuscript and circulated to all NAIMS
members in attendance. Edits and feedback were incorporated until all authors were in agreement.
Results
A wide spectrum of imaging techniques and analysis methods in the context of specific study
designs were discussed, with a focus on the utility and limitations of applying each technique to
assess neuroprotection and repair. Techniques were discussed under specific themes, and
included conventional imaging, magnetization transfer ratio, diffusion tensor imaging,
susceptibility-weighted imaging, imaging cortical lesions, magnetic resonance spectroscopy,
PET, advanced diffusion imaging, sodium imaging, multimodal techniques, imaging of special
regions, statistical considerations, and study design.
Conclusions
Imaging biomarkers of neuroprotection and repair are an unmet need in MS. There are
a number of promising techniques with different strengths and limitations, and selection of
a specific technique will depend on a number of factors, notably the question the trial seeks to
answer. Ongoing collaborative efforts will enable further refinement and improved methods to
image the effect of novel therapeutic agents that exert benefit in MS predominately through
neuroprotective and reparative mechanisms.
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The treatment landscape for multiple sclerosis (MS) has
changed dramatically, with a substantial increase in the
number of disease-modifying treatments (DMTs). DMTs
that exert beneficial effects through neuroprotective or neu-
rorepair mechanisms are the new frontier of MS therapeutics,
and developing accurate imaging measures of neuro-
protection and repair for proof-of-concept clinical trials is an
unmet need. This consensus statement builds upon prior
reports1 and summarizes current and emerging imaging
techniques to assess neuroprotection and repair, discusses the
advantages and disadvantages of each technique, and provides
a consensus opinion on the potential utility of each technique
in clinical trials, based on up-to-date evidence and expert
opinion.
Methods
Clinicians and scientists with expertise in the use of MRI
in MS convened in Toronto, Canada, in November 2016 at
a North American Imaging in Multiple Sclerosis (NAIMS)
Cooperative workshop meeting.2 A wide spectrum of im-
aging techniques was discussed in the context of specific
study designs, with a focus on the utility and limitations
of applying each technique to assess neuroprotection
and repair. The discussion was compiled into a manu-
script and circulated to all members in attendance. Edits
and feedback were incorporated until all authors were in
agreement.
General discussion points
This summary distinguishes between repair and neuro-
protection, recognizing that strategies aiming to repair tissue
damage could also be considered neuroprotective.3 Here,
“repair” refers to strategies aiming to reverse tissue damage
and “neuroprotection” to strategies aiming to prevent neu-
roaxonal loss. The focus is on measures with group-level
utility; application in individual patients is a clear limita-
tion of most of the techniques discussed. Whole-brain at-
rophy, currently the most widely used method in MS
clinical trials to measure disease progression and poten-
tially neuroprotection, has been reviewed extensively
elsewhere4,e1; the focus here is on emerging techniques
specifically discussed at the workshop. Key points are
summarized in table 1.
Repair of acute white matter (WM) lesions
Recovery of tissue integrity months after acute lesion for-
mation in MS includes both remyelination and axonal repair.5
Imaging this recovery process is important for the evaluation
of experimental agents that promote repair.
Conventional imaging
Historically, the most commonly applied MRI measure of
acute lesion repair is monitoring T1 hypointensity evolution
over time; lesions that show substantial residual tissue
damage demonstrate persistent T1 hypointensity (black
holes).6 At the time of lesion formation, most lesions show
T1 hypointensity due to edema, and persistence of T1
hypointensity pathologically correlates with loss of axons.e2
Clinical trials often use reduced conversion of acute lesions
to black holes to demonstrate a protective effect of DMTs.
An effect on black hole conversion and black hole volume
has been demonstrated in clinical trials with β-interferon,e3
glatiramer acetate, natalizumab,e4 fingolimod,e5 dimethyl
fumarate,e6 teriflunomide,e7 alemtuzumab,e8 and ocrelizu-
mab.e9 However, a limitation of the detection of black holes
is that it is highly dependent on MRI sequence and field
strength used.e10 Gadolinium enhancement patterns have
also been used to determine the evolution of lesions and may
relate indirectly to repair. The presence of nodular vs ring
enhancement has been considered, and the centripetal dy-
namic pattern of enhancement has been proposed to signify
incipient lesion repair.7,e11 The relative intensity of signal
change has also been used as a marker for tissue repair,8 and
sample size estimates using proton density–weighted signal
have been published.e12 Postmortem examination shows
good correlation between proton density signal intensity
and myelin.e13 Conventional MRI measures leverage the
routine collection of such data on scanners in wide clinical
use. The largest drawback is that the measures lack patho-
logic specificity and require signal normalization.9,10,e14–e17
The greatest utility of these techniques may be the ability to
demonstrate a failure to exert neuroprotective or reparative
effects.
Magnetization transfer ratio (MTR)
MTR is a semi-quantitative index sensitive to myelin that
measures the exchange of magnetization between protons
bound in macromolecules—in WM, commonly myelin mem-
brane constituents—to unrestricted protons in free water.
Glossary
ATP = adenosine triphosphate; DMT = disease-modifying treatment; DTI = diffusion tensor imaging; FLAIR = fluid-
attenuated inversion recovery; GCIP = ganglion cell + inner plexiform layer; GM = gray matter; ISC = intracellular sodium
concentration; LME = leptomeningeal enhancement; MR = magnetic resonance; MRS = magnetic resonance spectroscopy;
MS = multiple sclerosis; MTR = magnetization transfer ratio; MWF = myelin water fraction; MWI = myelin water imaging;
NAA = N-acetylaspartate; NAIMS = North American Imaging in Multiple Sclerosis; NODDI = neurite orientation dispersion
and density imaging;OCT = optical coherence tomography; pRNFL = peripapillary retinal nerve fiber layer thickness;QSM =
quantitative susceptibility mapping; RD = radial diffusivity; RRMS = relapsing-remitting multiple sclerosis; SC = spinal cord;
SWI = susceptibility-weighted imaging; TSC = total sodium concentration; TSPO = translocator protein;WM = white matter.
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MTR changes have been shown to correlate with histopatho-
logic evidence of demyelination and remyelination.11,e18 Al-
though sensitive to myelin, the magnitude of magnetization
transfer can be affected by edema, inflammation, and axonal
density, reducing its specificity. Nonetheless, MTR can be
implemented on most clinical scanners, with reasonable ac-
quisition times, high precision,e19 and simple postacquisition
processing algorithms.
The feasibility of measuring dynamic changes in MTR in acute
gadolinium-enhancing lesions has been demonstrated. With
acute lesion formation, average lesional MTR has been shown
to initially decrease, then increase—changes that are partially
related to edema but also reflect demyelination followed by
partial remyelination.12,e20–e22 In individual lesions, MTR
changes correlate with the degree of remyelination and clinical
improvement after intervention.13 Differential effects on MTR
recovery in acute lesions have been demonstrated for specific
therapies, suggesting variations in remyelination capacity
(figure 1).14,e23
Sample sizes for detecting therapeutic effects with MTR are
reasonable (table 2). When assessing MTR in individual
lesions (which is twice as efficient as averaging MTR across all
lesions), an experimental agent with a remyelinating effect
size of 30% could be detected with sample sizes of 20–40 per
study arm.15
Challenges of MTR include its sensitivity to acquisition
parameters and field strength, pathologic nonspecificity, and
nonlinear relationship with myelin density. Approaches to ad-
dress these limitations have been developed and can be
implemented in multicenter clinical trials.16,e24 MTR remains
a promising technique to assess remyelination, and one of the
few semi-quantitative myelin measures that has been applied
widely in clinical trials. What remains unknown is whether,
given the dominant contribution of myelin to the WM MRI
signal, other approaches with better signal-to-noise character-
istics, such as proton density–weighted imaging, could be even
more useful, despite their lesser pathologic specificity.
Diffusion tensor imaging (DTI)
DTI evaluates the 3D diffusion of water molecules in brain tissue
(figure 2).17 Several DTI-derived measures are sensitive to my-
elin content, particularly radial diffusivity (RD). RD captures
water diffusion perpendicular to the main direction of diffusion
(axial diffusivity) and increases with demyelination. Water
molecules are constrained in their diffusion with demyelination
along the perpendicular axis and then return to normal with
remyelination, as demonstrated in animalmodels.e25 Increases in
RD are most apparent in acute MS lesions,17 where increases in
RD predict conversion to persistent T1 hypointensity. RD also
shows measurable recovery after acute lesion formation. Al-
though recovery is variable, stabilization of RD values is typically
seen at 6 months.e26
Although DTI has limited specificity for myelin or axonal in-
tegrity, is sensitive to motion, and is cumbersome to analyze,
several studies have demonstrated its utility in multicenter
settings,18 with reasonable scan–rescan reliability across plat-
forms. A recent NAIMS study showed that DTI reliability was
high in a single patient with MS scanned at several sites.e27
Repair of chronic WM lesions
Imaging repair of chronicWM lesions poses several additional
challenges compared to acute lesions, as the dynamic range of
changes is expected to be small, and pathologic underpinnings
of chronic lesions can be complex. Despite these challenges,
several MRImeasures can be used to target specific pathologic
processes within chronic lesions.
Myelin water imaging (MWI)
Myelin is an obvious target for imaging repair of chronic
WM lesions. MWI is a technique that allows imaging of
myelin-associated water19 and has been validated in chronic
WM lesions in postmortem humanse28 and animals.e29 Al-
though MWI can also be applied to normal-appearing WM
to image neuroprotection and repair, this is not discussed as
a separate section due to space constraints.
Chronic lesions show abnormalities in myelin water fraction
(MWF) as well as heterogeneity across chronic lesion types,
e.g., in relation to T1 hypointense vs isointense lesions.20
Further work is needed to refine our understanding of long-
term myelin loss in such lesions. In acute lesions, MWI studies
show that the highest rate of myelin recovery occurs within the
first months after gadolinium enhancement and that sub-
sequent lesion myelin content is dependent upon the initial
MWF values, which reflects both myelin loss and edema.21
MWI is potentially an attractive option for clinical trials
given its relative specificity to myelin, good intrasite and
intersite reliability,22 and reproducibility across platforms.
Figure 1 Dynamic changes in magnetization transfer ratio
(MTR) in an acute multiple sclerosis lesion:
Potential utility in assessing novel therapeutics
GM = gray matter; WM = white matter. Published with permission from
Robert Brown.
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One historical drawback is the relatively long sequence ac-
quisition times.e30,e31 Recent advances have allowed for more
viable scan times23,e31−e33 at a voxel size sufficient to charac-
terize most chronic lesions,e28,e34 but these newer approaches
require histologic validation. Furthermore, MWF is a relative
measurement and may be confounded by changes in water
content, which can result in a falsely diluted measurement in
edematous acute MS lesions.e35 Approaches have been de-
veloped to measure absolute myelin water content using
brain CSF as a reference after correcting for the spatial in-
homogeneity of T1, receiver coil sensitivity, and excitation
flip angle.24,e36 MWI may be implemented in studies ex-
amining either neuroprotective effects or remyelination in
chronic lesions.
Susceptibility-weighted imaging (SWI)
A second potential target for imaging neuroprotection and
repair of chronic lesions involves probing the magnetic
susceptibility of tissue. The main contributors to brain pa-
renchymal magnetic susceptibility are diamagnetic myelin
and paramagnetic iron.e37 Quantitative susceptibility
mapping (QSM) is a postprocessing technique based on the
phase of susceptibility-weighted MRI25,26,e38 that enables a di-
rect measure of tissue susceptibility and overcomes the non-
local problem in T2*-weighted and phase imaging, though
image quality may be slightly compromised. Loss of myelin and
deposition of iron both increase the magnetic susceptibility.
Many early and intermediate-aged WM lesions (up to 4 years)
show increased susceptibility compared to normal-appearing
WM, which may, in principle, be due to loss of myelin or iron
accumulation.27,28 However, pathologic and MRI histology
studies have reported iron dispersed throughout individual le-
sion tissue in only a minority of chronic MS lesions, whereas
most MS lesions exhibit central iron loss,29–31,e39,e40 suggesting
that changes in magnetic susceptibility within lesions are
mostly due to changes in myelin.
While myelin loss is the main reason for increased magnetic
susceptibility of MS lesions, some chronic lesions exhibit
a paramagnetic rim on SWI—particularly on phase and QSM
images, but often on T2*-weighted images (and maps) as well
(figure 3).31,32,e41,e42 Multiple studies have shown that this
Table 2 Sample sizes per arm for neuroprotection or repair: proof-of-concept clinical trials
Sequence/












Gd lesions Lesions 36 22 14 van den Elskamp et al.b,e22
Gd lesions 24 12 Brown et al.e141
T2 lesions 84 38 21 14 Altmann et al.15
DTI Supratentorial white matter
FA 259 Harrison et al.e156
RD 105
Thalamic volume Thalamus 311 109 Kim et al.c,e87
Azevedo et al.a,49
Spinal cord CSA C2/C3 Cawley et al.e157
PPMS 157 57
SPMS 1538 546
Progressive MS 401 146
OCT GC/IP 258 119 68 44 Syc et al.d,e113
Brain volume Whole brain 140 58 Moccia et al.e,e158
PD New lesions >15 mm3 9 Reich et al.f,e12
Abbreviations: CSA = cross-sectional area; DTI = diffusion tensor imaging; FA = fractional anisotropy; GC/IP = ganglion cell layer/inner plexiform layer; Gd =
gadolinium; MTR = magnetization transfer ratio; OCT = optical coherence tomography; PD = proton density; PPMS = primary progressive multiple sclerosis;
RD = radial diffusivity; SPMS = secondary progressive multiple sclerosis.
All sample size calculations assume 80% power, α 0.05, and a 2-year trial length, unless otherwise specified.
a Maximal effect size = 60%, assuming clinically isolated syndrome, relapsing-remitting multiple sclerosis, and SPMS.
b Assumption of no treatment variance and 4 Gd lesions per patient.
c Assumption of 1-year trial, raw volumes.
d Assumption of 6-month trial.
e Assumption 90% power, patients with SPMS, SIENA method.
f Assumption 90% power, 6-month, placebo-controlled add-on trial, using 25th percentile of normalized PD-weighted signal.
Neurology.org/N Neurology | Volume 92, Number 11 | March 12, 2019 525
Copyright © 2019 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
rim is due to the presence of iron within phagocytes and is
a feature of chronic active (also known as slowly expanding
and smoldering) lesions, around which the previously un-
involved WM slowly degenerates. Rims are almost never seen
in remyelinated or inactive lesions,31,32 though they can be
seen in acute lesions, marking the locus of blood–brain barrier
leakage. Acute lesions that develop paramagnetic rims by 3
months after onset tend to have less volume decrease and
more T1 hypointensity over the first year.e43
Considering the above, susceptibility-based imaging and
QSM may be useful in proof-of-concept clinical trials
Figure 3 Susceptibility-weighted imaging
Persistent phase rims in a gadolinium-enhancing lesion in a patient with secondary progressive multiple sclerosis. Postcontrast T1-weighted images
demonstrate gadolinium enhancement evolution from centrifugal to centripetal. A hypointense rim can be visualized on noncontrast phase imageswhen the
lesion enhances centripetally, and is persistent after enhancement resolution (months 3, 6, 12, 18) and on T2*weighted images (months 6, 12, 18). MPRAGE =
magnetization-prepared rapid gradient echo. Reproduced with permission from Absinta M, Sati P, Schindler M, et al. Persistent 7-tesla phase rim predicts
poor outcome in new multiple sclerosis patient lesions. J Clin Invest 2016;126:2597–2609.
Figure 2 Theoretical basis of diffusion imaging
(A)Water diffusion along intact axonal fiber tracts in intact brain tissue. (B) Dispersedwater diffusion in brain tissuewith demyelination and axonal injury. The
arrows indicate the primary, second, and third eigenvectors of the diffusion tensor. Reprinted with permission, Cleveland Clinic Center for Medical Art &
Photography © 2004–2018. All Rights Reserved.
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assessing both neuroprotection and remyelination. Advan-
tages are high spatial resolution with short data acquisition
times, high signal-to-noise ratio, exquisite sensitivity to changes
in tissue composition, and wide availability of the scan.
Drawbacks include complicated and not-yet-standardized
data processing, which requires the exclusion of paramagnetic
central veins,e44 as well as the need for careful and nuanced
interpretation.
PET imaging
PET allows directly imaging pathologic substrates of
chronic lesions. 11C-MeDAS (N-[11C]methyl-4,49-dia-
minostilbene), studied in animals, is sensitive to both de-
myelination and remyelination.33 Another tracer, Pittsburgh
compound B ([methyl-11C]-2-[49-methylaminophenyl]-6-
hydroxybenzothiazole), has demonstrated sensitivity for
myelin in animal studies34 and changes in chronicMS lesions
in humans, potentially identifying remyelination.e45
Several PET tracers have been developed to image activated
microglia. The translocator protein (TSPO), a mitochondrial
membrane cholesterol transporter, is a putative biomarker for
activated microglia. The most frequently used pharmaceutical
tracer has been [11C]-(R)-PK11195, which shows a rim pat-
tern colocalizing with activated microglia in chronic active
lesions.35 However, specificity for activated microglia is not
complete, as PK11195 also binds to reactive astrocytes.
Second-generation TSPO ligands include over 50 different
potential compounds, including 11C-PBR28, 18F-PBR111,
and 18F-DPA714. The use of second-generation TSPO radi-
oligands may be limited in clinical trials as genetic poly-
morphisms affecting binder affinity are frequent.e46
Overall, PET is a promising technology for measuring repair
of acute lesions in relation to myelin, microglia, and other
pathologic processes. Lack of widespread tracer availability,
expertise required for implementation, high expense, low
spatial resolution, and radiation exposure (especially with
repeat dosing) remain barriers to implementation in multi-
center clinical trials. In the future, PET, or PET/MRI, may be
useful for experimental therapeutics targeting specific cells or
pathways.
Repair of cortical lesions
Cortical lesions are a key component of MS pathology and
a significant correlate of neurologic disability.36,e47,e48 Cortical
lesions can be divided into 3 major typese48: leukocortical,
intracortical, and subpial.
The relatively low myelin content in the cortex has limited the
ability to visually detect cortical lesions at standard field
strengths. Voxel-wise or vertex-wise analyses of cortical myelin
integrity can overcome some of the limitations of visual cortical
lesion–based analyses.37,e49−5155 A series of semi-quantitative
(MTR, DTI, diffusion kurtosis, T1-weighted/T2-weighted ra-
tio) and quantitative (T2, T2*, T1) magnetic resonance (MR)
contrasts can be used,37,e52,53 as well as myelin-sensitive PET
radiotracers.34 As for WM lesions, no imaging quantity is en-
tirely myelin-specific.
At clinical field strengths, dedicated MRI sequences such as
double inversion recovery and phase sensitive inversion re-
covery can detect cortical lesions in all stages of MS.38,e54,55
The sensitivity of these protocols to subpial demyelination,
however, remain limited. 7T MRI greatly increases de-
tection of cortical MS lesions,39 but this is dependent on
cortical lesion type, with T2*-weighted MRI providing
a relative benefit compared to other contrasts in detecting
subpial lesions.40 In histopathologic–MRI correlative stud-
ies, sensitivities for 7T T2*-weighted MRI to cortical lesions
vary from ;35%–47% (prospective) to ;63%–93% (ret-
rospective),39,e42,56 suggesting a need for optimization and
standardization of acquisition and evaluation procedures.
Statistical models combining MR contrasts can increase
specificity to different aspects of cortical pathology. A recent
multivariate model using different MR contrasts to account
for confounding factors (iron, B0, cortical thickness) esti-
mated myelin distribution in the cortex from quantitative T2*
at 7T and MTR at 3T.41 Myelin estimation obtained with this
model showed similar trends to histopathology.41
With further validation, techniques that detect cortical lesions
or evaluate cortical myelin could be useful as measures of
neuroprotection or repair in proof-of-concept studies. Fur-
thermore, PET-based assessment of cortical microglial acti-
vation could provide information to stage cortical lesions and
stratify patients based on their remyelination potential.e57,e58
A number of limitations preclude widespread use of these
measures, including the small size of cortical lesions and
complex cortical geometry. 7T imaging remains the most
sensitive platform for cortical lesion detection, but the tech-
nology is only now starting to gain wide availability.
Repair of energy deficits
Predictors of brain tissue loss may ultimately become the
target of the next generation of DMTs, with the goal of
identifying the underlying biology leading to, and tissue at risk
for, neurodegeneration. Several brain metabolites measured
with MR spectroscopy (MRS) may have promise as upstream
predictors and can provide insights into cellular energy me-
tabolism, mitochondrial function, or oxidative stress.
Previous studies have demonstrated that mitochondrial en-
ergy failure leading to oxidative stress plays a central role in
MS-related axonal degeneration, preceding structural brain
atrophy.e59 1H-MRS metabolites reflecting cellular energy
status in MS include N-acetylaspartate (NAA), creatinine/
phosphocreatine, and glutathione.e60 NAA is interpreted as
a marker of neuroaxonal integrity reflecting both structural
density and mitochondrial function.42,e61 Decreased NAA is
seen in acute and chronic MS lesions and in normal-appearing
WM, and may precede brain atrophy.42,e61−e65
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Recent MRS research has focused on glutamate and gluta-
thione dysregulation. During acute MS injury, activated
macrophages/microglia release glutamate into the extracel-
lular compartment,e66 where there is defective glutamate
uptake by oligodendrocytes.e67 This initiates an oxidative
cascadee68,e69 leading to the overproduction of reactive oxy-
gen species, neuronal mitochondrial dysfunction,e70−e72 re-
duced adenosine triphosphate (ATP), and ionic imbalance.
Glutathione is an antioxidant essential for protecting against
reactive oxygen species. In vivo 1H-MRS imaging has dem-
onstrated a reduction of glutathione in the gray matter (GM)
and focal lesions,43,e73 suggesting that patients with MS may
lack the ability to produce sufficient glutathione in the pres-
ence of a glutamate stimulus.
As a direct measure of high-energy phosphates (ATP and
phosphocreatine), phosphorus (31P)-MRS may provide
additional insight into energy metabolism in MS. Using
single-voxel 31P-MRS imaging at 7T, combined with 1H-
MRS, high-energy phosphates can be reduced in GM,44 which
may predict brain atrophy. In addition, dynamic contrast
techniques such as brain capillary water lifetime are under
development to measure cellular water cotransport, which is
proportional to plasma membrane P-type ATPase turnover
and may offer additional insight into cellular energy metab-
olism.e74,e75 Although still in early phases of investigation, this
technique could eventually complement established MRS
methods and offer high spatial resolution maps of brain
metabolic activity.
At present, these metabolic markers might be most useful to
probe biological mechanisms in the context of proof-of-
concept clinical trials. Several technical challenges limit their
utility as primary endpoints for multicenter clinical trials, in-
cluding low spatial resolution as well as variability in metab-
olite quantification across scanners.
Repair and neuroprotection of axons at risk
Axonal integrity can be preserved by enhancing remyelination
or promoting neuroprotection. This section discusses
emerging techniques to quantify axonal density that have
mainly been applied within MS lesions.
Advanced diffusion imaging
Several advanced diffusion MRI techniques can quantitatively
assess axon density with improved specificity to tissue micro-
structure changes. DTI’s specificity for axon integrity is di-
minished in the presence of acute inflammation and chronic
tissue loss.e76 A number of more complex compartment-
specificmodels attempt to address this limitation by accounting
for intra-axonal, extra-axonal, and free water diffusion.45
Diffusion basis spectrum imaging aims to evaluate the aniso-
tropic component of diffusion, to account for cellularity and
extracellular space.e77 Other approaches such as AxCaliber and
ActiveAx can additionally provide information on axon di-
ameter but may require high gradient MR systems to provide
robust data.e78,e79 Models such as neurite orientation disper-
sion and density imaging (NODDI) provide information on
axon density and variation of fiber orientation with improved
clinical feasibility.e80
In the corpus callosum, AxCaliber has been applied in MS
to demonstrate increased axon diameter and decreased
axonal density within lesions.e79 NODDI can also detect de-
creased axon density and increased orientation dispersion in
lesions.e80 In the setting of axonal loss, techniques such as
AxCaliber may provide useful information regarding axon di-
ameter distribution that could identify the size of axons at
greatest risk of damage and dropout.
These advanced diffusion techniques may be of utility as
measures of neuroprotection in single-center trial settings.
Limitations include that many of these diffusion models are
insensitive at probing small-diameter axons using conven-
tional magnetic field gradientse81 and the need for pathologic
correlational studies. While high-gradient-strength MR sys-
tems are becoming more prevalent, limited availability cur-
rently makes multicenter application a challenge.
Sodium imaging
23Na MRI quantifies the tissue total sodium concentration
(TSC), representing the weighted average of intracellular and
extracellular 23Na. Intra-axonal accumulation of 23Na ions,
determined by Na/K pump dysfunction, increases TSC.46
While TSC increase in chronic lesions might be explained by
gliosis, tissue disruption, and replacement with extracellular
fluid, TSC increase in nonchronic lesions and normal-
appearing brain tissue is related not only to increased extra-
cellular space, but also to the increase of intracellular sodium
concentration (ISC).
In patients with MS, ISC increase may reflect axonal dysfunc-
tion, offering insights into axonal metabolism before the gen-
eration of stable, irreversible, axonal damage. Since ISC
accumulation is a reversible phenomenon occurring spontane-
ously in a number of neurons in physiologic conditions, it could
be a putative target for therapeutic interventions, providing
a better tool to investigate the neuroprotective effects of ex-
perimental therapies in early, proof-of-concept clinical trials.e82
One notable limitation of sodium imaging technique is its low
spatial resolution. This is somewhat improved by increasing
field strength to 7T, with inherent challenges to multicenter
application.
Multimodal approaches
Since myelin and axonal integrity influence one another, any
study design assessing for improvement in myelin content
may consider including a measure of axonal content (to select
patients most likely to respond to remyelinating therapies)
and vice versa. Multimodal approaches that incorporate in-
formation about the integrity of both, such as in vivo g-ratio
estimation (defined as the ratio between the inner and the
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outer diameter of the myelin sheath), could also prove useful,
if validated.e83,e84
Repair and neuroprotection of special regions
Deep GM
The deep GM nuclei are affected by several aspects of the MS
disease process.e85 Although a number of deep GM structures
are highly relevant,e86,e87 we focus here on the thalamus as
a region of particular interest.
Recent literature suggests that thalamic volume is a promising
MRI measure of neurodegeneration, and potentially useful as
a primary endpoint in phase II clinical trials. As a major relay
center, the thalamus is involved in a wide range of neurologic
functions and may be particularly vulnerable to upstream or
downstream neurodegeneration due to axonal transection
within WM lesions.e88 Axonal transection is likely a major
contributor to the reduction in thalamic volume seen histo-
pathologically,e89 but iron depositione85 and demyelinating
lesions47,48 may also contribute.e41,e90,e91 Thalamic volume
measurements by MRI likely reflect the net effects of these
processes, and hence can be considered a barometer for
overall tissue damage in MS.48,e92
The presence of thalamic atrophy on MRI has been reported
cross-sectionally in early phases of demyelinating disease, in-
cluding CIS,49,e93 pediatric MS,e94 and radiologically isolated
syndrome.e95 Thalamic volume correlates well with physicale90
and cognitive disability.e96 Importantly, the rate of thalamic
volume decline has been shown to be consistent throughout
the MS disease duration, and sample-size calculations in-
corporating normal aging have yielded practical estimates for
phase II clinical trials (table 2).49,e87 Emerging post hoc and
prespecified clinical trial data suggest that thalamic atrophy is
modifiable with DMT.49,e97
Thalamic volume is a promising endpoint associated with neu-
rodegenerative aspects of MS, making it a potentially useful
measure of neuroprotection in phase II clinical trials. One limi-
tation is that it is a small structure not well-defined on conven-
tional images, which can lead to high measurement variability.
Hippocampus
The hippocampus is a complex GM structure situated within
the mesial temporal lobe with several subregions of differing
histology, functional specificity, and susceptibility to disease
processes in MS.e98,e99 The hippocampus forms the neuroan-
atomical foundation for declarative memory functions and is
also implicated in emotional responses and mood regulation.
The hippocampus is a frequent target of disease effects in MS,
as shown by structural and functional imaging50,51,e100−e103 and
neuropathologic studies.e104−e106 Widespread demyelination,
neuronal loss, and diminished dendritic density may be
seen,e103,e105−e107 but not all pathologic changes have been
tied directly to inflammatory activity.e104,e105,e107,e108 MRI
can detect hippocampal atrophy in early stages of relapsing-
remitting MS (RRMS), affecting the CA1 subregion pref-
erentially and associated with deficits in verbal memory.e102
Depression and altered cortisol secretion patterns in RRMS
are associated with additional hippocampal changes, in-
cluding in subregion CA3.e102,e108,e109
Several hippocampal MRI measures could be sensitive and
specific primary endpoints for studies focused on memory
impairment and depression, making it relevant to neuro-
protection and repair. Although not yet validated for use in
clinical trials, hippocampal atrophy, surface-based topology,
subregional changes, and connectivity are currently under
study. Future work should focus on longitudinal changes in
these measures, their relationship to clinical endpoints, and
the effect of neuroprotective treatments.
Retina
Optical coherence tomography (OCT) is a noninvasive, in-
expensive, and reproducible imaging technique that generates
high-resolution images of the retina, allowing most individual
layers to be quantified. In MS, pathologic studies have shown
that ;80% of cases demonstrate ganglion cell layer nuclear
dropout, and 40% had inner nuclear layer (amacrine and bi-
polar cell) loss.e110
Reductions in OCT-derived peripapillary retinal nerve fiber
layer thickness (pRNFL) and ganglion cell + inner plexiform
layer (GCIP) thickness are observed in patients with MS with
and without a history of optic neuritis.52 GCIP thickness has
demonstrated superior reliability and reproducibility and cor-
relates better with visual function and disability in MS than
pRNFL.e110 Rates of GCIP thinning are accelerated in patients
with MS exhibiting inflammatory activity, correlate strongly
with rates of whole-brain and GM atrophy over time, and are
modulated by DMTs.53,e111 Longitudinal studies of 5- and 10-
year follow-up periods show that baseline OCT predicts
changes in Expanded Disability Status Scale.54
There are several different spectral-domain OCT scanners in
use, and cross-platform comparison of data remains an issue. On
the other hand, retinal segmentation algorithms that can perform
longitudinal analyses of data acquired on the same scanner allow
an assessment of individual rates of change over time, which can
be compared across scanners.e112
Given the ease of implementation, OCT-derived metrics
could be useful as an outcome measure in phase II neuro-
protection trials. Sample size calculations to detect a 50%
reduction in GCIP thinning following acute optic neuritis are
reasonable (44–59 subjects per arm, table 2).e113 While
achieving neuroprotection is a great need in progressive MS,
establishing efficacy with OCT may be more challenging, as
the annual rate of change is less than in RRMS. Another
potential application of OCT is as a screening tool for
remyelinating clinical trials to select patients with less axonal
loss who may therefore have the potential to respond to
a remyelinating therapy.
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Limitations of OCT include its restriction to the retina and that
annual changes at the cohort level (0.5–1.5 μm) are less than
individual variability in scanner reproducibility (2–4 μm).
Spinal cord (SC)
Conventional SC measures
The SC is a compact structure organized into functional
columns. It is frequently affected in all stages of MSe114 and
contributes substantially to disability. As such, it is a useful
structure to assess neuroprotective and repair mechanisms of
candidate drugs.
Clinical imaging of the SC has mostly been geared toward
lesion detection,e114 and clinical correlations with SC lesion
count and volume in patients with MS have been limit-
ed.e114−e116 Although SC lesions can theoretically assess re-
pair in a similar manner to acute brain lesions, technical
difficulties with SC lesion detection using conventional
sequences limits the utility of this approach. Recent advances
in MRI sequences may make it possible to utilize the de-
velopment and evolution of acute lesions in the SC to mea-
sure neuroprotection and repair in the future.e117
SC atrophy
The most commonly utilized quantitative SC measure has
been assessing atrophy via the upper SC cross-sectional area
(figure 4). Strong correlations have been demonstrated with
clinical disability, across all stages of MS.55,e118 Furthermore,
rates of SC atrophy have been reported to be up to 2% per
year and are accelerated in progressive MS, making this
measure a potential candidate to assess neuroprotection and
even repair.e119 The greatest limitation preventing widespread
use of SC atrophy is measurement variability. Recent studies
have identified that SC GM atrophy often occurs in early
RRMS, prior to the onset of general atrophy.56 However, this
measure can be difficult to obtain in the presence of focal SC
lesions. Further validation and refinement of methods to
measure SC GM may eventually make this an attractive
measure of neuroprotection for experimental drugs in early
trial settings, particularly for progressive MS.e119
Advanced SC imaging
More advanced imaging techniques have been applied to
the SC in MS, including DTI, MTI (figure 4), MWI, and
fMRI.57,e120−e122 Most of these techniques have benefits over
conventional techniques as they can quantify underlying tis-
sue changes and have demonstrated robust correlations with
clinical disability. However, measurement variability and
complexity of image analysis limit their practical use in
detecting neuroprotection or repair in clinical trials.
Leptomeninges
Interest in the leptomeningeal compartment has increased in
recent years, as accumulating evidence confirms the impor-
tance of leptomeningeal inflammation and colocalizing
subpial demyelination in mediating disability in all stages of
MS.e123
Leptomeningeal inflammation has been difficult to visualize
with conventional techniques, but recent studies have repor-
ted the presence of leptomeningeal enhancement (LME) in
MS on T2–fluid-attenuated inversion recovery (FLAIR) MRI
performed at least 10 minutes after IV gadolinium adminis-
tration. In one study, LME was observed with a prevalence of
25% in a cohort of patients with relapsing and progressiveMS;
Figure 4 Quantitative spinal cord MRI measures
(A, B) Automated segmentation of spinal cord cross-sectional area. (C) Color-
codeddiffusion tensor imagingmap (derived from fractional anisotropy and
the principal eigenvector) demonstrates spinal cord fibers running along the
rostrocaudal axis (blue). Reproduced with permission from Oh J, Sotirchos
ES, Saidha S, et al. Relationships between quantitative spinal cord MRI and
retinal layers in multiple sclerosis. Neurology 2015;84:720–728.
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prevalence was highest in those with primary progressive MS
(;40%) and correlated with disability scores.58 The patho-
logic correlate of LME was explored in 2 autopsy cases that
localized LME with inflammatory cell aggregates around
meningeal vessels in close proximity to subpial cortical de-
myelination. More recent studies using modifications of the
FLAIR technique (subtraction imaging, 7T) report an even
higher prevalence of LME (50%–90%)e124 and an association
of LME with more rapid GM atrophy at 5 years.59
LME imaging is in early stages of development and requires
clarification on prevalence, optimal acquisition technique, and
treatment responsiveness. Morphologically similar LME is
also prevalent in other neuroinflammatory diseases.e125 If
validated to be relevant to progressive disease initiation and
propagation in MS, the presence/absence of LME may
emerge as a measure to monitor candidate drugs with neu-
roprotective effects.
Study design and statistical considerations
Although imaging measures of neuroprotection can some-
times be used to measure repair, important study design
considerations may differ between these 2 categories. Mea-
suring neuroprotection requires an appropriate comparator
group, because it would otherwise be difficult to demonstrate
tissue loss that did not occur in an individual or group of
patients. Repair may be more absolute with imaging methods
targeting the re-emergence of tissue that was previously
damaged (figure 1).
Another study design consideration for many of the techni-
ques discussed is that it may be useful to make the unit of
observation an MS lesion, rather than an individual patient.
This has substantial implications for sample size and power
calculations but must be done with caution, since imaging
features in different lesions within the same individuals are
likely to be correlated.
Intersite and scanner variability in MRI-derived metrics remain
a major issue in multicenter studies.e126−e133 Statistical tech-
niques such as mixed-effects models applied to extracted bio-
markers have traditionally been used to address this problem,
but these approaches do not completely take into account all
sources of variability, particularly when multimodal techniques
are used. More advanced statistical techniques, including
corrections applied directly on images or to panels of radiomic
features, may allow a more comprehensive accounting of
sources of variability, and techniques used will have to be
tailored to specific quantitative MRI techniques.9,60,e134−e139
Furthermore, variability related to segmentation and regis-
tration methodology must be considered when uniform
processing methods are applied across sites.10,e140
Longitudinal, multimodal MRI (conventional and advanced)
of acute WM lesions presents an opportunity to extract both
temporally and spatially consistent information that reflects
tissue damage and repair. By integrating intensity patterns
before, at, and after lesion formation, and modeling trajecto-
ries using advanced statistical approaches,e141−e146 new bio-
markers that are more correlated to disease-related changes
and therapeutic effects may be developed. In the future, by
leveraging changes in the local intermodality covariance
structure,8,e147 these measures may be able to disentangle
demyelinating changes, repair process, and imaging artifacts,
providing more sensitive and specific markers for thera-
peutic trials.
Discussion
Imaging biomarkers of neuroprotection and repair are needed
to accelerate the discovery of effective treatments for all stages
of MS. Based on the collective opinion of the NAIMS Co-
operative, it is evident there are a number of promising
techniques with different strengths and limitations. Selection
of a specific technique will depend on a number of factors,
including clinical setting, outcome being targeted, study de-
sign, mechanisms of action of candidate drugs, patient pop-
ulation, and resources. Advanced statistical methods can be
applied to different techniques in multicenter settings to ac-
count for variability and to extract important information that
may be useful to model neuroprotection and repair. Ongoing
collaborative efforts will enable further refinement and im-
proved methods to image the effects of novel therapeutic
agents in MS predominately through neuroprotective and
reparative mechanisms.
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